Wyrick Robbins Yates & Ponton LLP
4101 Lake Boone Trail, Suite 300
Raleigh, North Carolina 27607
Donald R. Reynolds
dreynolds@wyrick.com
June 3, 2010
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, DC 20549
Attention: Rose Zukin
| Re: | Pharmaceutical Product Development, Inc. |
Form 10-K for the year ended December 31, 2009
Filed February 26, 2010
Schedule 14A filed April 1, 2010
File No. 000-27570
Ladies and Gentlemen:
We write this letter on behalf of our client Pharmaceutical Product Development, Inc. (the “Company”) in response to the comments of the Staff of the Securities and Exchange Commission with respect to the above-captioned filing, as set forth in the Staff’s letter dated May 26, 2010. In a telephone conversation on June 2, 2010, between the undersigned and Rose Zukin of the Staff, the undersigned conveyed the Company’s request to extend the deadline to respond to the Staff’s comments to June 23, 2010. This letter will serve to memorialize that request.
U.S. Securities and Exchange Commission
June 3, 2010
Page 2 of 2
If the Staff has any further comments, please direct them to the undersigned.
| Sincerely, |
| /s/ Donald R. Reynolds |
| Donald R. Reynolds |
| cc: | Daniel Darazsdi |
Judd Hartman
